Stock Track | Moderna Plunges Over 21% as Weak Vaccine Demand Slashes 2025 Revenue Forecast

Stock Track

Jan 13, 2025

Moderna Inc. (MRNA) witnessed a steep pre-market decline of 21.18% on Monday, as the biotechnology company slashed its 2025 revenue forecast, citing sluggish launch of its respiratory syncytial virus (RSV) vaccine mRESVIA and waning demand for COVID-19 vaccines.

The company now expects its 2025 revenue to range between $1.5 billion and $2.5 billion, marking a significant reduction from its previous projection of $2.5 billion to $3.5 billion. This revised forecast fell short of analysts' average estimate of $2.95 billion for the year.

The disappointing outlook reflects the challenges Moderna is facing in its transition from its pandemic-driven success with COVID-19 vaccines. As the demand for these shots wanes, the company's newly launched RSV vaccine, mRESVIA, has also faced a lackluster reception, with negligible sales reported.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1184355298"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1184355298\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1184355298?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-13 22:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184355298","market":"us","top_or_hot":-1,"title":"Stock Track | Moderna Plunges Over 21% as Weak Vaccine Demand Slashes 2025 Revenue Forecast","media":"Stock Track","content":"<p>Moderna Inc. (MRNA) witnessed a steep pre-market decline of 21.18% on Monday, as the biotechnology company slashed its 2025 revenue forecast, citing sluggish launch of its respiratory syncytial virus (RSV) vaccine mRESVIA and waning demand for COVID-19 vaccines.</p>\n\n<p>The company now expects its 2025 revenue to range between $1.5 billion and $2.5 billion, marking a significant reduction from its previous projection of $2.5 billion to $3.5 billion. This revised forecast fell short of analysts' average estimate of $2.95 billion for the year.</p>\n\n<p>The disappointing outlook reflects the challenges Moderna is facing in its transition from its pandemic-driven success with COVID-19 vaccines. As the demand for these shots wanes, the company's newly launched RSV vaccine, mRESVIA, has also faced a lackluster reception, with negligible sales reported.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Moderna Plunges Over 21% as Weak Vaccine Demand Slashes 2025 Revenue Forecast</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Moderna Plunges Over 21% as Weak Vaccine Demand Slashes 2025 Revenue Forecast\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-01-13 22:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna Inc. (MRNA) witnessed a steep pre-market decline of 21.18% on Monday, as the biotechnology company slashed its 2025 revenue forecast, citing sluggish launch of its respiratory syncytial virus (RSV) vaccine mRESVIA and waning demand for COVID-19 vaccines.</p>\n\n<p>The company now expects its 2025 revenue to range between $1.5 billion and $2.5 billion, marking a significant reduction from its previous projection of $2.5 billion to $3.5 billion. This revised forecast fell short of analysts' average estimate of $2.95 billion for the year.</p>\n\n<p>The disappointing outlook reflects the challenges Moderna is facing in its transition from its pandemic-driven success with COVID-19 vaccines. As the demand for these shots wanes, the company's newly launched RSV vaccine, mRESVIA, has also faced a lackluster reception, with negligible sales reported.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1184355298","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184355298","pubTimestamp":1736778882,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Moderna Inc.  witnessed a steep pre-market decline of 21.18% on Monday, as the biotechnology company slashed its 2025 revenue forecast, citing sluggish launch of its respiratory syncytial virus  vaccine mRESVIA and waning demand for COVID-19 vaccines.The company now expects its 2025 revenue to range between $1.5 billion and $2.5 billion, marking a significant reduction from its previous projection of $2.5 billion to $3.5 billion. This revised forecast fell short of analysts' average estimate of ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"由于疫苗需求疲软导致2025年收入预测大幅下降，Moderna股价暴跌超过21%","themeId":"ff122fd480f2bbc039a7eeb6471c3f96","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"Moderna Inc. (MRNA) witnessed a steep pre-market decline of 21.18% on Monday, as the biotechnology company slashed its 2025 revenue forecast, citing sluggish launch of its respiratory syncytial virus (RSV) vaccine mRESVIA and waning demand for COVID-19 vaccines.\nThe company now expects its 2025 revenue to range between $1.5 billion and $2.5 billion, marking a significant reduction from its previous projection of $2.5 billion to $3.5 billion. This revised forecast fell short of analysts' average estimate of $2.95 billion for the year.\nThe disappointing outlook reflects the challenges Moderna is facing in its transition from its pandemic-driven success with COVID-19 vaccines. As the demand for these shots wanes, the company's newly launched RSV vaccine, mRESVIA, has also faced a lackluster reception, with negligible sales reported.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}